Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

GHRP-2 vs GHRP-6

Peptide Schedule Research TeamReviewed Sep 24, 20269 Citations

vs

GHRP-2 and GHRP-6 are synthetic growth hormone secretagogues that act on the ghrelin receptor. Both trigger a short GH pulse after each dose. The difference people talk about most is hunger, and the research on that is thinner than the community consensus.

GHRP-2
Growth Hormone~33 min

A 38% decline in peak GH response from day one to day five. That finding comes from Nijland and colleagues (Eur J Endocrinol 1998), who dosed nine healthy young men at 100 mcg/day subcutaneous (PMID 9820615). It shaped how experienced users run GHRP-2 today. GHRP-2, also called pralmorelin (CAS 158861-67-7), is a synthetic hexapeptide growth hormone secretagogue. It binds GHS-R1a on pituitary somatotrophs, mimicking ghrelin to trigger a rapid, dose-dependent GH pulse. Compared to GHRP-6, it reached half its maximal GH effect at a lower dose in a swine study (Raun 1998). Community reports describe less appetite stimulation, though a human study found GHRP-2 raised food intake 35.9% (PMID 15699539). In the same swine study, GHRP-2 worked at a lower dose than ipamorelin, but ipamorelin reached the higher GH peak (PMID 9849822). GHRP-2 also raised ACTH and cortisol in those swine, and ipamorelin did not. No human study has compared the two. The practical community protocol runs 100 to 200 mcg subcutaneous two to three times daily on an empty stomach, co-injected with CJC-1295 (no DAC) for complementary GHRH + GHRP stimulation. That combination produces two to three times the GH pulse of either peptide alone, according to consistent user reports across hundreds of Reddit threads. Cycling is mandatory: 5 days on, 2 days off within each week, plus 8 weeks on, 4 weeks off for the gross cycle. Japan's PMDA approved GHRP-2 (brand name GHRP Kaken 100) in 2004 as a single-dose IV diagnostic agent for GH deficiency. No country has approved it therapeutically. Over 200 PubMed papers cover its pharmacology, but most are mechanistic or short-term. No long-term therapeutic RCT exists for the doses the community uses. The evidence base is strong on mechanism and acute pharmacology; it's thin on multi-month safety at 100 to 300 mcg SC daily.

View full guide →
GHRP-6
Growth Hormone7.6 min distribution, 2.5 h elimination (IV)

GHRP-6 (Growth Hormone Releasing Peptide-6, CAS 87616-84-0) is a synthetic hexapeptide that binds the growth hormone secretagogue receptor (GHS-R1a) at the pituitary gland. In swine, its peak GH level was similar to ipamorelin's (PMID 9849822), but the trade-offs are real. Cabrales and colleagues characterized its pharmacokinetics in nine healthy male volunteers using IV administration (PMID 23099431), landing on a distribution half-life of 7.6 minutes and an elimination half-life around 2.5 hours. The commonly cited plasma half-life sits at roughly 20 minutes. What separates GHRP-6 from cleaner secretagogues like ipamorelin is its ghrelin mimicry. GHS-R1a is the ghrelin receptor, so agonism there doesn't just release GH. It also triggers orexigenic signaling that makes appetite spike within 20 minutes of injection. Cortisol and prolactin rise as well. In Bowers' study of 18 healthy men, both roughly doubled at 1 mcg/kg IV but not at lower doses (PMID 2108187). Taken orally or intranasally, GHRP-6 left cortisol unchanged (PMID 10336729). Community adoption across thousands of users on r/Peptides and bodybuilding forums has been consistent for over a decade. The top protocol pairs 100 mcg GHRP-6 with 100 mcg CJC-1295 No DAC (Mod GRF 1-29), injected two to three times daily on an empty stomach. Users report improved sleep, faster recovery, and lean mass accrual over 8 to 12 week cycles. No randomized controlled trials exist for body composition outcomes in healthy adults; the evidence base for performance use relies on GH-stimulation data extrapolated through community experience.

View full guide →

At a Glance

GHRP-2 moleculeGHRP-2GHRP-6 moleculeGHRP-6
CategoryGrowth HormoneGrowth Hormone
Safety GradeBB
Half-Life~33 min7.6 min distribution, 2.5 h elimination (IV)
RouteSubcutaneousSubcutaneous
Vial Sizes5 mg5 mg
Beginner Dose100 mcg Daily100 mcg Daily
Moderate Dose200 mcg 2x Daily200 mcg 2x Daily
Aggressive Dose200 mcg 3x Daily300 mcg 3x Daily
Dosing SourceCommunityCommunity
Side EffectsReceptor desensitization is the most clinically documented concern. Nijland et al. (1998) tracked peak GH falling from 83 to 51 µg/L, about 38%, from day one to day five at 100 mcg/day subcutaneous in nine healthy young men (PMID 9820615). This is not a theoretical risk; it's measured and reproducible. Without cycling (5 days on, 2 days off minimum), the peptide loses a third of its effectiveness within a week. Users who skip cycling waste product and lose the GH output they're paying for. Cortisol elevation is real but transient. Arvat et al. (PMID 9285939) documented mild ACTH and cortisol spikes post-injection that return to baseline within two to three hours. At standard doses (100 to 200 mcg once or twice daily), this rarely causes symptoms. Long-term cortisol data for GHRP-2 itself are lacking. In adults on hexarelin, a related GHRP, 16 weeks of twice-daily injections lowered the cortisol response (PMID 10341859). Their prolactin response did not change. On three times daily advanced protocols, watch for disrupted sleep, irritability, or stubborn fat gain around the midsection. Get an AM cortisol lab at week eight if running the advanced protocol. Prolactin elevation follows a similar pattern: mild, transient, dose-dependent. Symptomatic hyperprolactinemia (libido changes, gynecomastia) is uncommon at standard doses but warrants lab work if symptoms appear. The prolactin burden is similar to hexarelin's at equal doses (PMID 9285939) but higher than ipamorelin's. Appetite increase hits 20 to 30 minutes after injection. GHRP-2 mimics ghrelin at GHS-R1a, and ghrelin is the hunger hormone. The effect is significantly less intense than GHRP-6 but more pronounced than ipamorelin. For cutting protocols, this can be disruptive. Shifting the bedtime dose to three or more hours after dinner (still fasted) helps manage it. Water retention and mild edema are GH-class effects, not specific to GHRP-2. Expect some puffiness in the first two to four weeks that stabilizes. Injection-site reactions include transient tingling and dizziness lasting 5 to 15 minutes post-injection. These are common, benign, and tend to diminish over the first week. Carpal tunnel symptoms (hand tingling, grip weakness) signal excessive GH-mediated fluid retention. Reduce dose or frequency immediately. If symptoms persist beyond one week at a lower dose, discontinue for a minimum of four weeks. GH antagonizes insulin action, and GHRP-2's cortisol co-elevation compounds this effect. Monitor fasting glucose at baseline and at weeks four and eight. Pre-diabetic individuals should check weekly. A fasting glucose above 125 mg/dL warrants dose reduction and medical review. Contraindications: active cancer or history of malignancy (GH promotes cell proliferation), uncontrolled diabetes or diabetic retinopathy, pregnancy or breastfeeding, active pituitary tumors, and known hypersensitivity to pralmorelin. No human data exists on multi-month subcutaneous dosing safety at the doses the community uses.The most serious concern with GHRP-6 is its effect on blood glucose regulation. Growth hormone directly opposes insulin action, and GHRP-6 compounds this problem by driving appetite-fueled caloric surpluses that can push fasting glucose upward. Anyone with uncontrolled diabetes, insulin resistance, or prediabetes should treat this as a hard contraindication. Fasting glucose monitoring every four weeks during a cycle isn't optional at this dosing level. Cortisol elevation is the second concern worth weighing carefully. GHRP-6 mildly raises ACTH and cortisol. Frieboes and colleagues saw both rise after four 50 mcg IV doses at night in healthy men (PMID 7617137). Their 1999 follow-up found oral and intranasal GHRP-6 left cortisol unchanged (PMID 10336729). At 100 mcg once daily, this is generally subclinical. Long-term cortisol data for GHRP-6 are lacking. In adults on hexarelin, a related GHRP, 16 weeks of twice-daily injections lowered the cortisol response (PMID 10341859). At 200 to 300 mcg three times daily, watch for slower recovery, poorer sleep or stalled fat loss. Users running aggressive protocols should check morning cortisol at week four. Prolactin elevation also occurs, more so than with ipamorelin. At aggressive doses, some users report symptoms consistent with raised prolactin. Baseline and week-four prolactin checks are warranted if dosing exceeds 200 mcg per injection. Published side effects from the pharmacokinetic literature include tingling, facial flushing, dizziness, and transient warmth, all of which represent normal GH-pulse effects and typically resolve within 30 to 60 minutes. Community reports confirm these; they're predictable and dose-dependent. Water retention is common at higher doses (200 to 300 mcg range). Users report two to four pounds of water weight during peak dosing weeks. This resolves within one to two weeks of dose reduction or cessation. The appetite effect deserves its own warning. At 300 mcg, hunger becomes genuinely difficult to manage. This is a ghrelin mimetic doing exactly what ghrelin does. Users attempting to use GHRP-6 during a caloric deficit generally abandon the attempt; this peptide is a bulking tool. Injection site reactions (redness, mild irritation) are possible with any subcutaneous peptide. Pregnancy and breastfeeding are absolute contraindications. No human safety data exists for these populations.

Key Differences

  • GHRP-2 is the more potent of the two per dose, at least in swine. In conscious swine, GHRP-2 reached half its maximal GH effect at 0.6 nmol/kg, against 3.9 nmol/kg for GHRP-6, though GHRP-6 reached a higher peak [1]. In people, Bowers' 1993 summary reported that GHRP-2 released GH more effectively than GHRP-6 [9]. Its abstract gives no doses or group sizes for that ranking.

  • Both release GH strongly in people. In 6 young adults, IV GHRP-2 at 1 mcg/kg produced a larger GH response than GHRH [2]. In healthy men, four 50 mcg IV boluses of GHRP-6 roughly tripled night-time GH against placebo [3].

  • Both can raise ACTH and cortisol. In swine, GHRP-2 and GHRP-6 both raised them [1]. In healthy adults, GHRP-2 raised prolactin, ACTH and cortisol [2], and GHRP-6 raised ACTH and cortisol after IV doses [3]. Taken orally or intranasally, GHRP-6 did not raise cortisol [4]. No trial has compared the two on these hormones.

  • Hunger is where the community and the data part ways. Community reports cast GHRP-6 as the hunger peptide and GHRP-2 as the milder pick. Yet the one human food-intake study cited here tested GHRP-2 [5]. After a 270-minute subcutaneous infusion, 7 lean men ate 35.9% more at a buffet. So GHRP-2 raises appetite too; how far apart the two are has not been measured.

  • Daily use blunts the response. Nine healthy men took 100 mcg of GHRP-2 subcutaneously once a day for 5 days [6]. Peak GH fell from 83 to 51 mcg/l, and IGF-1 did not rise.

  • Measured half-lives come from different designs, so they do not compare cleanly. GHRP-2's was about 33 minutes after an IV dose in children [7]. GHRP-6's elimination half-life was 2.5 hours after IV doses in adult men [8].

When to Choose GHRP-2

  • Appetite stimulation is unwanted, as in a cutting phase (community reports; GHRP-2 still raised food intake in one human study)[5]

  • A lower dose per GH response appeals (swine potency data)[1]

  • Less hunger matters more than peak GH (community reports)

When to Choose GHRP-6

  • You want appetite stimulation for bulking or weight gain (community reports)

  • Stronger hunger is a benefit for you (community reports)

  • You're in a mass-gain or recovery phase

Verdict

In people and animals, both peptides release GH and raise ACTH and cortisol, and GHRP-2 is the more potent per dose in swine [1]. Community reports split them by hunger, with GHRP-6 as the bulking choice. One human study shows GHRP-2 raises food intake too [5], so "less hunger" is relative, not a guarantee.

Research peptides with both sides of the evidence.

Published studies and community reports, side by side, for 150+ peptides. Save the ones you are weighing and see when anything changes.

Can You Stack GHRP-2 + GHRP-6?

Not Recommended

GHRP-2 and GHRP-6 target the same receptor (GHS-R). Community protocols stack either one with CJC-1295 instead, for a combined GHRH + GHRP effect.

Dosage Calculators

Or use the universal Peptide Calculator for any peptide.

Explore all Growth Hormone peptides

Peptide Schedule Research TeamReviewed Sep 24, 20269 Citations

References

  1. [1]Ipamorelin, the first selective growth hormone secretagogue (Raun et al., Eur J Endocrinol 1998) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]GHRP-2 and hexarelin effects on GH, prolactin, ACTH and cortisol in man (Arvat et al., Peptides 1997) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]GHRP-6 stimulates sleep, GH, ACTH and cortisol release in normal man (Frieboes et al., Neuroendocrinology 1995) (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]GHRP-6 and nocturnal GH, ACTH and cortisol by route of administration (Frieboes et al., J Neuroendocrinol 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]GHRP-2, like ghrelin, increases food intake in healthy men (Laferrere et al., J Clin Endocrinol Metab 2005) (opens in a new tab)PubMed (opens in a new tab)PubMed
  6. [6]Five days of daily subcutaneous GHRP-2 attenuate the GH response in healthy young men (Nijland et al., Eur J Endocrinol 1998) (opens in a new tab)PubMed (opens in a new tab)PubMed
  7. [7]Pharmacokinetics and pharmacodynamics of GHRP-2, a phase I study in children (Pihoker et al., J Clin Endocrinol Metab 1998) (opens in a new tab)PubMed (opens in a new tab)PubMed
  8. [8]Pharmacokinetics of GHRP-6 in nine healthy male volunteers (Cabrales et al., Eur J Pharm Sci 2013) (opens in a new tab)PubMed (opens in a new tab)PubMed
  9. [9]GH releasing peptides: structure and kinetics, a summary of GHRP-6, GHRP-1 and GHRP-2 studies in people (Bowers, J Pediatr Endocrinol 1993) (opens in a new tab)PubMed (opens in a new tab)PubMed

Frequently Asked Questions

Community reports say GHRP-6, by a wide margin, and many pick it for bulking for that reason. The human data is thinner. The one food-intake study cited here tested GHRP-2. After a 270-minute subcutaneous infusion, 7 lean men ate 35.9% more (PMID 15699539). No human study has measured the two side by side.

Both can raise cortisol, at least acutely. In swine, both raised ACTH and cortisol (PMID 9849822). In healthy adults, IV GHRP-2 raised cortisol and prolactin (PMID 9285939), and IV GHRP-6 raised ACTH and cortisol (PMID 7617137). Oral and intranasal GHRP-6 left cortisol unchanged in one study (PMID 10336729).

The response fades but does not stop. Nine healthy men took 100 mcg of GHRP-2 once daily for 5 days (PMID 9820615). Their peak GH fell from 83 to 51 mcg/l, and IGF-1 did not rise.

They work on the same target, the growth hormone secretagogue receptor (PMID 15699539), so stacking them adds a second agonist to one receptor. Community protocols pair either one with a GHRH analog such as CJC-1295 instead. No trial has tested GHRP-2 with GHRP-6.
9 references